No products in the cart.
Rabbit Polyclonal Anti-MLL antibody (STJ98732)
Supplier: St John’s Laboratory Ltd.
Recommended applications: IHC-P, ELISA
Recommended dilution: IHC-P 1:50-300; ELISA 1:5000-20000
Recommended protocols: check protocols
Click or hover above images to see image description for Anti-MLL antibody.
Check alternative names for the antibodyExpand
|ALL-1 antibody|ALL1 antibody|C-terminal cleavage product of 180 kDa antibody|CXXC-type zinc finger protein 7 antibody|CXXC7 antibody|HRX antibody|HTRX1 antibody|KMT2A antibody|Lysine N-methyltransferase 2A antibody|Mll antibody|MLL cleavage product C180 antibody|MLL1 antibody|MLL1_HUMAN antibody|MLL1A antibody|N-terminal cleavage product of 320 kDa antibody|p180 antibody|p320 antibody|Trithorax-like protein antibody|TRX1 antibody|Zinc finger protein HRX antibody|Anti-KMT2A / MLL antibody [mmN4.4] (ab32400)
SCBT cat No: sc-101431|sc-18214|sc-377274|sc-30729|sc-374392|sc-20153|sc-53371|sc-30730|
|Catalogue No.|| |
Human, Mouse, Rat
Anti-MLL antibody detects endogenous MLL.
Synthetic peptide from human protein at AA range: 3850-3900.
|Recommended dilution|| |
IHC-P 1:50-300; ELISA 1:5000-20000
Anti-MLL antibody was tube-contained in PBS, pH 7.4, containing 0.02% sodium azide as Preservative and 50% Glycerol.
Anti-MLL antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
ALL-1 antibody, ALL1 antibody, C-terminal cleavage product of 180 kDa antibody, CXXC-type zinc finger protein 7 antibody, CXXC7 antibody, HRX antibody, HTRX1 antibody, KMT2A antibody, Lysine N-methyltransferase 2A antibody, Mll antibody, MLL cleavage product C180 antibody, MLL1 antibody, MLL1_HUMAN antibody, MLL1A antibody, N-terminal cleavage product of 320 kDa antibody, p180 antibody, p320 antibody, Trithorax-like protein antibody, TRX1 antibody, Zinc finger protein HRX antibody
|Database links|| |
|Protein function|| |
Histone methyltransferase that plays an essential role in early development and hematopoiesis. Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of ‘Lys-4’ of histone H3 (H3K4me) complex and acetylation of ‘Lys-16’ of histone H4 (H4K16ac). In the MLL1/MLL complex, it specifically mediates H3K4me, a specific tag for epigenetic transcriptional activation. Has weak methyltransferase activity by itself, and requires other component of the MLL1/MLL complex to obtain full methyltransferase activity. Has no activity toward histone H3 phosphorylated on ‘Thr-3’, less activity toward H3 dimethylated on ‘Arg-8’ or ‘Lys-9’, while it has higher activity toward H3 acetylated on ‘Lys-9’. Required for transcriptional activation of HOXA9. Promotes PPP1R15A-induced apoptosis. Plays a critical role in the control of circadian gene expression and is essential for the transcriptional activation mediated by the CLOCK-ARNTL/BMAL1 heterodimer. Establishes a permissive chromatin state for circadian transcription by mediating a rhythmic methylation of ‘Lys-4’ of histone H3 (H3K4me) and this histone modification directs the circadian acetylation at H3K9 and H3K14 allowing the recruitment of CLOCK-ARNTL/BMAL1 to chromatin (By similarity). .
|Protein tissue specificity|| |
Heart, lung, brain and T- and B-lymphocytes.
|Involvement in disease|| |
Wiedemann-Steiner syndrome (WDSTS) [MIM:605130]: A syndrome characterized by hairy elbows (hypertrichosis cubiti), intellectual disability, a distinctive facial appearance, and short stature. Facial characteristics include long eyelashes, thick or arched eyebrows with a lateral flare, and downslanting and vertically narrow palpebral fissures. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Note=Chromosomal aberrations involving KMT2A are a cause of acute leukemias. Translocation t(1;11)(q21;q23) with MLLT11/AF1Q; translocation t(3;11)(p21;q23) with NCKIPSD/AF3p21; translocation t(3,11)(q25,q23) with GMPS; translocation t(4;11)(q21;q23) with AFF1/MLLT2/AF4; insertion ins(5;11)(q31;q13q23) with AFF4/AF5Q31; translocation t(5;11)(q12;q23) with AF5-alpha/CENPK; translocation t(6;11)(q27;q23) with AFDN; translocation t(9;11)(p22;q23) with MLLT3/AF9; translocation t(10;11)(p11.2;q23) with ABI1; translocation t(10;11)(p12;q23) with MLLT10/AF10; t(11;15)(q23;q14) with CASC5 and ZFYVE19; translocation t(11;17)(q23;q21) with MLLT6/AF17; translocation t(11;19)(q23;p13.3) with ELL; translocation t(11;19)(q23;p13.3) with MLLT1/ENL; translocation t(11;19)(q23;p23) with GAS7; translocation t(X;11)(q13;q23) with FOXO4/AFX1. Translocation t(3;11)(q28;q23) with LPP. Translocation t(10;11)(q22;q23) with TET1. Translocation t(9;11)(q34;q23) with DAB2IP. Translocation t(4;11)(p12;q23) with FRYL. Fusion proteins KMT2A-MLLT1, KMT2A-MLLT3 and KMT2A-ELL interact with PPP1R15A and, on the contrary to unfused KMT2A, inhibit PPP1R15A-induced apoptosis. .; Note=A chromosomal aberration involving KMT2A may be a cause of chronic neutrophilic leukemia. Translocation t(4;11)(q21;q23) with SEPT11. .
|Protein sequence and domain|| |
Belongs to the class V-like SAM-binding methyltransferase superfamily. Histone-lysine methyltransferase family. TRX/MLL subfamily. ; Contains 3 A.T hook DNA-binding domains. ; Contains 1 bromo domain. ; Contains 1 C2HC pre-PHD-type zinc finger. ; Contains 1 CXXC-type zinc finger. ; Contains 1 FYR C-terminal domain. ; Contains 1 FYR N-terminal domain. ; Contains 4 PHD-type zinc fingers. ; Contains 1 post-SET domain. ; Contains 1 SET domain. The 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors. ; The SET domain structure is atypical and is not in an optimal position to have methyltransferase activity. It requires other components of the MLL1/MLL complex, such as ASH2L or RBBP5, to order the active site and obtain optimal histone methyltransferase activity. ; The CXXC-type zinc finger binds bind to nonmethyl-CpG dinucleotides.
|Protein post-translational modifications|| |
Proteolytic cleavage by TASP1 generates MLL cleavage product N320 and MLL cleavage product C180, which reassemble through a non-covalent association. 2 cleavage sites exist, cleavage site 1 (CS1) and cleavage site 2 (CS2), to generate MLL cleavage products N320 and C180. CS2 is the major site. .
|Protein cellular localization|| |
Nucleus .; MLL cleavage product N320: Nucleus.; MLL cleavage product C180: Nucleus. Note=Localizes to a diffuse nuclear pattern when not associated with MLL cleavage product N320.
AntibodyPlus can customize Anti-MLL antibody according to your requirement, including bulk product size,etc. Please contact firstname.lastname@example.org. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: